Table 3.

Distribution of the factor product type utilization reported by participants according to inhibitor history.

Product Type	No History of an Inhibitor (N=695)	History of an Inhibitor (N=101)
Recombinant	625	70
Plasma-derived	39	2
Plasma-derived with VWF	3	0
Recombinant & Plasma-derived	8	1
Recombinant & Plasma-derived with VWF	6	0
Plasma-derived & Plasma-derived with VWF	1	0
Bypass/Prothrombin Complex	1	11
Bypass/Prothrombin Complex & Recombinant	4	9
Bypass/Prothrombin Complex & Plasma-derived	1	0
Bypass/Prothrombin Complex & Plasma-derived with VWF	0	3
Bypass/Prothrombin Complex & Recombinant & Plasma-derived with VWF	1	5
Other	6	0